Advisors Capital Management LLC Lowers Stock Holdings in Eli Lilly and Company $LLY

Advisors Capital Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 6.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,921 shares of the company’s stock after selling 726 shares during the period. Advisors Capital Management LLC’s holdings in Eli Lilly and Company were worth $7,734,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Willner & Heller LLC lifted its holdings in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock valued at $705,000 after purchasing an additional 13 shares in the last quarter. Braun Bostich & Associates Inc. increased its stake in shares of Eli Lilly and Company by 2.5% during the second quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock worth $411,000 after purchasing an additional 13 shares in the last quarter. Rise Advisors LLC raised its position in shares of Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company’s stock worth $571,000 after purchasing an additional 13 shares during the last quarter. Occidental Asset Management LLC lifted its stake in Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after buying an additional 13 shares in the last quarter. Finally, New Insight Wealth Advisors boosted its holdings in Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after buying an additional 13 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. BMO Capital Markets increased their target price on Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. UBS Group boosted their price target on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, November 3rd. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $999.28.

Eli Lilly and Company Trading Up 0.2%

NYSE LLY opened at $1,024.67 on Friday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a market capitalization of $968.70 billion, a P/E ratio of 66.97, a PEG ratio of 1.21 and a beta of 0.43. The firm’s 50-day moving average is $826.89 and its two-hundred day moving average is $780.87. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,033.62.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.